Charlotte leads the Gates Foundation Venture Capital initiative and oversees investing in innovative technologies that support the foundation’s programs in global health and agriculture. She currently serves on the board of directors of Synlogic, Sera Prognostics, Lodo Therapeutics, Omniome, and Vir Biotechnology.
Prior to joining the foundation, Charlotte was a vice president at H.I.G. BioVentures, investing broadly in healthcare. Charlotte began her career in early stage biotech, investing at Accelerator Corporation, where she was part of the founding team and oversaw management of five companies: Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori, and Pharmselex.
Charlotte earned a B.S. in microbiology from the University of Washington and a Ph.D. in pharmacology and cancer biology from Duke University for which she received the prestigious Harold Weintraub Award. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the UW. Charlotte is a member of the Kauffman Society of Fellows (Class 14) and serves on the BOD of Life Science Washington and the steering committee of the Fred Hutch Cancer Institute’s Evergreen Fund. Charlotte was recently honored as a Fierce Woman in Biopharma 2016 by FiercePharma, and as a leading Woman in Life Sciences 2016 by Life Science Washington.Back to all team members